Extracellular Vesicles as Non-coding RNA Delivery Systems in Inflammatory and Immunological Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 8225

Special Issue Editors


E-Mail Website1 Website2
Guest Editor
Cardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, Avd. Menendez Pelayo, accesorio 4, 46010 Valencia, Spain
Interests: drug delivery systems; non-coding RNA; extracellular vesicles; exosomes; blood-urine-renal delivery; renal glomerular crosstalk; translational research
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
"T-cell Tolerance, Biomarkers and Therapies in Type 1 Diabetes" Team, Université de Paris, Institut Cochin, CNRS, INSERM, 75014 Paris, France
Interests: resolution of inflammation, type 1 diabetes; T cell autoreactive responses; lipid mediators; extracellular vesicles; beta cells; macrophages
Cardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
Interests: extracellular vesicles; miRNAs; renal damage study in biofluids and cell cultures; therapeutic delivery systems

Special Issue Information

Dear Colleagues,

In recent years, extracellular vesicles, nanometer-sized lipid-bilayer-enclosed, have attracted increasing attention due to their inherent ability to shuttle proteins, lipids and genes between cells and their natural affinity to target cells. Their intrinsic features such as stability, biocompatibility, low immunogenicity and ability to overcome biological barriers, have prompted interest in their use as drug delivery vehicles, mainly on the transfer of non-coding RNAs (key functional components of gene expression through their roles in alternative splicing, epigenetic regulation, mRNA turnover and translational repression), being an informed way to treat severe and harming pathologies such as the inflammatory and immunological diseases.

This Special Issue’s goal is to highlight the current state of the art and contemporary progress in this field. We invite review or original articles on all aspects of “Extracellular vesicles as non-coding RNA delivery systems in inflammatory and immunological diseases”.

Dr. Raquel Cortes Vergaz
Dr. Javier Perez-Hernandez
Dr. Ana Ortega
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extracellular vesicles
  • exosomes
  • non-coding RNA
  • immunological disease
  • inflammatory disease
  • delivery systems

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1341 KiB  
Review
Mesenchymal Stem Cell-Derived Extracellular Vesicles as Non-Coding RNA Therapeutic Vehicles in Autoimmune Diseases
by Olga Martinez-Arroyo, Ana Ortega, Maria J. Forner and Raquel Cortes
Pharmaceutics 2022, 14(4), 733; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14040733 - 29 Mar 2022
Cited by 11 | Viewed by 4591
Abstract
Autoimmune diseases (ADs) are characterized by the activation of the immune system against self-antigens. More common in women than in men and with an early onset, their incidence is increasing worldwide, and this, combined with their chronic nature, is contributing to an enlarged [...] Read more.
Autoimmune diseases (ADs) are characterized by the activation of the immune system against self-antigens. More common in women than in men and with an early onset, their incidence is increasing worldwide, and this, combined with their chronic nature, is contributing to an enlarged medical and economic burden. Conventional immunosuppressive agents are designed to alleviate symptoms but do not constitute an effective therapy, highlighting a need to develop new alternatives. In this regard, mesenchymal stem cells (MSCs) have demonstrated powerful immunosuppressive and regenerative effects. MSC-derived extracellular vesicles (MSC-EVs) have shown some advantages, such as less immunogenicity, and are proposed as novel therapies for ADs. In this review, we summarize current perspectives on therapeutic options for ADs based on MSCs and MSC-EVs, focusing particularly on their mechanism of action exerted through their non-coding RNA (ncRNA) cargo. A complete state-of-the-art review was performed, centralized on some of the most severe ADs (rheumatoid arthritis, autoimmune type 1 diabetes mellitus, and systemic lupus erythematosus), giving evidence that a promising field is evolving to overcome the current knowledge and provide new therapeutic possibilities centered on MSC-EVs and their role as ncRNA delivery vehicles for AD gene therapy. Full article
Show Figures

Figure 1

20 pages, 1540 KiB  
Review
Exosomes as a New Delivery Vehicle in Inflammatory Bowel Disease
by Xiaomei Wang, Guoliang Zhou, Wanwan Zhou, Xin Wang, Xiao Wang and Chenggui Miao
Pharmaceutics 2021, 13(10), 1644; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13101644 - 09 Oct 2021
Cited by 10 | Viewed by 3019
Abstract
Inflammatory bowel disease (IBD) is a type of chronic relapsing inflammatory disease. The pathogenesis of IBD is still unclear, which may involve environmental factors, genetic factors, intestinal microbiota disorder, and abnormal immune responses. Exosomes (30–150 nm) are found in various body fluids, including [...] Read more.
Inflammatory bowel disease (IBD) is a type of chronic relapsing inflammatory disease. The pathogenesis of IBD is still unclear, which may involve environmental factors, genetic factors, intestinal microbiota disorder, and abnormal immune responses. Exosomes (30–150 nm) are found in various body fluids, including blood, saliva, urine, and cerebrospinal fluid. Exosomes mediate intercellular communication and regulate cell biological activity by carrying non-coding RNAs, proteins, and lipids. There is evidence that exosomes are involved in the pathogenesis of IBD. In view of the important roles of exosomes in the pathogenesis of IBD, this work systematically reviews the latest research progress of exosomes in IBD, especially the roles of exosomes as non-coding RNA delivery systems in the pathogenesis of IBD, including a disordered immune response, barrier function, and intestinal microbiota. The review will help to clarify the pathogenesis of IBD and explore new diagnostic markers and therapeutic targets for patients with IBD. Full article
Show Figures

Figure 1

Back to TopTop